Search

Your search keyword '"Vittecoq, Olivier"' showing total 694 results
Start Over Author "Vittecoq, Olivier"
694 results on '"Vittecoq, Olivier"'

201. Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: Evidence for tumor necrosis factor α-induced VE-cadherin cleavage

Author

Sidibé, Adama, primary, Mannic, Tiphaine, additional, Arboleas, Mélanie, additional, Subileau, Mariela, additional, Gulino-Debrac, Danielle, additional, Bouillet, Laurence, additional, Jan, Mary, additional, Vandhuick, Thibault, additional, Le Loët, Xavier, additional, Vittecoq, Olivier, additional, and Vilgrain, Isabelle, additional

Published
2011
Full Text
View/download PDF

204. L’infliximab à 3mg/kg en dose initiale dans la spondylarthrite active résistante aux traitements habituels est efficace, bien toléré et moins coûteux

Author

Tenga, Ginette, primary, Goëb, Vincent, additional, Lequerré, Thierry, additional, Bacquet-Deschryver, Hélène, additional, Daragon, Alain, additional, Pouplin, Sophie, additional, Lanfant-Weybel, Karine, additional, Le Loët, Xavier, additional, Dieu, Bernard, additional, and Vittecoq, Olivier, additional

Published
2011
Full Text
View/download PDF

205. A 3mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs

Author

Tenga, Ginette, primary, Goëb, Vincent, additional, Lequerré, Thierry, additional, Bacquet-Deschryver, Hélène, additional, Daragon, Alain, additional, Pouplin, Sophie, additional, Lanfant-Weybel, Karine, additional, Le Loët, Xavier, additional, Dieu, Bernard, additional, and Vittecoq, Olivier, additional

Published
2011
Full Text
View/download PDF

207. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: A simple model of prediction from a conservatively treated community-based inception cohort

Author

Loët, Xavier Le, primary, Brazier, Michel, additional, Mejjad, Othmane, additional, Boumier, Patrick, additional, Daragon, Alain, additional, Gayet, Alain, additional, Pouplin, Sophie, additional, Tron, François, additional, Zarnitsky, Charles, additional, Vittecoq, Olivier, additional, Menard, Jean-François, additional, and Fardellone, Patrice, additional

Published
2010
Full Text
View/download PDF

216. Early and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synovia

Author

Lequerré, Thierry, primary, Bansard, Carine, additional, Vittecoq, Olivier, additional, Derambure, Céline, additional, Hiron, Martine, additional, Daveau, Maryvonne, additional, Tron, François, additional, Ayral, Xavier, additional, Biga, Norman, additional, Auquit-Auckbur, Isabelle, additional, Chiocchia, Gilles, additional, Le Loët, Xavier, additional, and Salier, Jean-Philippe, additional

Published
2009
Full Text
View/download PDF

217. Smoking and inflammatory diseases

Author

Vittecoq, Olivier, primary, Lequerré, Thierry, additional, Goëb, Vincent, additional, Le Loët, Xavier, additional, Abdesselam, Tassadit Ait, additional, and Klemmer, Nathalie, additional

Published
2008
Full Text
View/download PDF

223. Reliability of histopathological salivary gland biopsy assessment in Sjögren’s syndrome: a multicentre cohort study.

Author

Costa, Sebastian, Quintin-Roué, Isabelle, Lesourd, Agnès, Jousse-Joulin, Sandrine, Berthelot, Jean-Marie, Hachulla, Eric, Hatron, Pierre-Yves, Goeb, Vincent, Vittecoq, Olivier, Pers, Jacques Olivier, Marcorelles, Pascale, Nowak, Emmanuel, Saraux, Alain, and Devauchelle-Pensec, Valérie

Abstract

Objective. The aim of this study was to assess intraobserver and interobserver reliability of minor salivary gland biopsy (MSGB) in SS. Methods. All MSGBs available from the Tolerance and Efficacy of Rituximab in Primary Sjögren’s Syndrome (TEARS) study were subjected to a standardized blinded assessment by a single specifically trained pathologist twice at a 2 month interval; both the Chisholm–Mason (CM) grade and the focus score (FS) were determined. Baseline histopathological reports by local pathologists at each study centre were compared with the first standardized blinded assessment. Agreement was assessed for the dichotomized FS (dFS) and dichotomized CM (dCM) grade, as well as for nine other histopathological features. Results. Eighty-nine MSGBs were studied. Intraobserver κ values were 1 for dFS, 0.80 for dCM, 0.67 for germinal centre-like structures, 0.44 for fibrosis and 0.29 for confluent foci. Most of the local histopathological reports based their diagnosis on the CM grade, although the FS was often reported or the data needed to determine it were provided. Interobserver agreement κ values were 0.71 for dFS, 0.64 for dCM, 0.46 for focal lymphocytic sialadenitis, 0.42 for non-specific chronic inflammation and 0.16 for fibrosis. Conclusion. Although FS reliability was good, disparities were noted in the assessment methods used by local pathologists. The protocol for FS determination was not followed routinely, with the result that the FS was often overestimated. Germinal centre-like structures, which predict lymphoma, showed good reliability but were inconsistently reported. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

224. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene.

Author

Gazal, Steven, Sacre, Karim, Allanore, Yannick, Teruel, Maria, Shigeto Tohma, Alfredsson, Lars, Yukinori Okada, Gang Xie, Constantin, Arnaud, Balsa, Alejandro, Kawasaki, Aya, Nicaise, Pascale, Amos, Christopher, Rodriguez-Rodriguez, Luis, Chiocchia, Gilles, Boileau, Catherine, Jinyi Zhang, Vittecoq, Olivier, Barnetche, Thomas, and Gay, Miguel A. Gonzalez

Abstract

Objective To evaluate the contribution of the SPP1 rs11439060 and rs9138 polymorphisms, previously reported as autoimmune risk variants, in the rheumatoid arthritis (RA) genetic background according to anticitrullinated protein antibodies (ACPAs) status of RA individuals. Methods We analysed a total of 11 715 RA cases and 26 493 controls from nine independent cohorts; all individuals were genotyped or had imputed genotypes for SPP1 rs11439060 and rs9138. The effect of the SPP1 rs11439060 and rs9138 risk-allele combination on osteopontin (OPN) expression in macrophages and OPN serum levels was investigated. Results We provide evidence for a distinct contribution of SPP1 to RA susceptibility according to ACPA status: the combination of ≥3 SPP1 rs11439060 and rs9138 common alleles was associated mainly with ACPA negativity (p=1.29 x10-5, ORACPA-negative 1.257 (1.135 to 1.394)) and less with ACPA positivity (p=0.0148, ORACPA-positive 1.072 (1.014 to 1.134)). The ORs between these subgroups (ie, ACPA-positive and ACPAnegative) significantly differed (p=7.33 x10-3). Expression quantitative trait locus analysis revealed an association of the SPP1 risk-allele combination with decreased SPP1 expression in peripheral macrophages from 599 individuals. To corroborate these findings, we found an association of the SPP1 risk-allele combination and low serum level of secreted OPN ( p=0.0157), as well as serum level of secreted OPN correlated positively with ACPA production (p=0.005; r=0.483). Conclusions We demonstrate a significant contribution of the combination of SPP1 rs11439060 and rs9138 frequent alleles to risk of RA, the magnitude of the association being greater in patients negative for ACPAs. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

225. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Author

Ternant, David, Ducourau, Emilie, Fuzibet, Piéra, Vignault, Céline, Watier, Hervé, Lequerré, Thierry, Le Loët, Xavier, Vittecoq, Olivier, Goupille, Philippe, Mulleman, Denis, and Paintaud, Gilles

Subjects
PHARMACOKINETICS, RHEUMATOID arthritis, ADALIMUMAB, C-reactive protein, SCIENTIFIC observation, DRUG administration, DRUG dosage
Abstract

Aims This study aimed at describing adalimumab pharmacokinetics ( PK) and the concentration-effect relationship of adalimumab using pharmacokinetic-pharmacodynamic ( PK-PD) modelling in patients with rheumatoid arthritis ( RA). Methods Adalimumab PK and PK-PD data were obtained from a multicentric observational study. Adalimumab (40 mg) was administered subcutaneously every other week, and its pharmacokinetics was described using a one-compartment model. The relationship between adalimumab concentration and C-reactive protein ( CRP) concentration was described using an indirect response model with inhibition of CRP input, whereas the relationship between adalimumab concentration and disease activity score in 28 joints ( DAS28) was described using a direct inhibition model. Dose regimens that included a loading dose of adalimumab were simulated. Results Thirty patients treated for RA were analysed. The following pharmacokinetic and PK-PD parameters were estimated (interidividual coefficient of variation): apparent volume of distribution ( Vd/ F) = 10.8 l (92%); apparent clearance ( CL/ F) = 0.32 l day−1 (17%); first-order absorption rate ( ka) = 0.28 day−1; CRP input ( kin) = 22.0 mg l−1 day−1 (65%); adalimumab concentration leading to a 50% decrease in kin ( C50) = 3.6 mg l−1 (88%); baseline DAS28 (DAS0) = 5.5 mg l−1 (11%); and adalimumab concentration leading to 50% decrease of DAS0 (IC50) = 11.0 mg l−1 (71%). Simulations showed that a 160 mg loading dose should reduce the time to reach efficacy in terms of both CRP and DAS28 after the first injection. Conclusions This is the first study to describe adalimumab pharmacokinetics and the concentration-effect relationship in RA. A 160 mg loading dose may lead to an increased benefit from treatment in RA patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

226. Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis

Author

Fautrel, Bruno, primary, Constantin, Arnaud, additional, Morel, Jacques, additional, Vittecoq, Olivier, additional, Cantagrel, Alain, additional, Combe, Bernard, additional, Dougados, Maxime, additional, Le Loët, Xavier, additional, Mariette, Xavier, additional, Pham, Thao, additional, Puéchal, Xavier, additional, Sibilia, Jean, additional, Soubrier, Martin, additional, and Ravaud, Philippe, additional

Published
2006
Full Text
View/download PDF

231. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Author

Lequerré, Thierry, primary, Gauthier-Jauneau, Anne-Christine, additional, Bansard, Carine, additional, Derambure, Céline, additional, Hiron, Martine, additional, Vittecoq, Olivier, additional, Daveau, Maryvonne, additional, Mejjad, Othmane, additional, Daragon, Alain, additional, Tron, François, additional, Le Loët, Xavier, additional, and Salier, Jean-Philippe, additional

Published
2006
Full Text
View/download PDF

237. Protéomique et auto-anticorps

Author

Machour, Nadine, primary, Gilbert, Danièle, additional, Vittecoq, Olivier, additional, Costa, Odile, additional, Tron, François, additional, and Charlionet, Roland, additional

Published
2005
Full Text
View/download PDF

243. Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination

Author

Vittecoq, Olivier, Guillou, Clément, Hardouin, Julie, Gerard, Baptiste, Berenbaum, Francis, Constantin, Arnaud, Rincheval, Nathalie, Combe, Bernard, Lequerre, Thierry, and Cosette, Pascal

Abstract

Background: To validate the ability of PROS (vitamin K-dependent protein S) and CO7 (complement component C7) to predict response to the methotrexate (MTX)/etanercept (ETA) combination in rheumatoid arthritis (RA) patients who received this therapeutic combination in a well-documented cohort. Method: From the ESPOIR cohort, RA patients having received the MTX/ETA or MTX/adalimumab (ADA) combination as a first-line biologic treatment were included. Serum concentrations of PROS and CO7 were measured by ELISA prior to the initiation of ETA or ADA, at a time where the disease was active (DAS28 ESR > 3.2). The clinical efficacy (response/non-response) of both combinations has been evaluated after at least 6 months of treatment, according to the EULAR response criteria with some modifications. Results: Thirty-two were treated by MTX/ETA; the numbers of responders and non-responders were 24 and 8, respectively. Thirty-three patients received the MTX/ADA combination; 27 and 5 patients were respectively responders and non-responders. While there were no differences for demographic, clinical, biological, and X-rays data, as well as for CO7, serum levels of PROS tended to be significantly higher in responders to the MTX/ETA combination (p= 0.08) while no difference was observed in the group receiving MTX/ADA. For PROS, the best concentration threshold to differentiate both groups was calculated at 40 μg/ml using ROC curve. The theranostic performances of PROS appeared better for the ETA/MTX combination. When considering the response to this combination, analysis of pooled data from ESPOIR and SATRAPE (initially used to validate PROS and CO7 as potential theranostic biomarkers) cohorts led to a higher theranostic value of PROS that became significant (p= 0.009). Conclusion: PROS might be one candidate of a combination of biomarkers capable of predicting the response to MTX/ETA combination in RA patients refractory to MTX. Trial registration: ClinicalTrials.gov identifiers: NCT03666091and NCT00234234.

Published
2022
Full Text
View/download PDF

246. Autoantibodies directed against the amino-terminal domain I of human calpastatin (ACAST-DI Ab) in connective tissue diseases. High levels of ACAST-DI Ab are associated with vasculitis in lupus

Author

Saulot, Vincent, primary, Vittecoq, Olivier, additional, Salle, Valery, additional, Drouot, Laurent, additional, Legoedec, Jocelyne, additional, Le Loët, Xavier, additional, Godin, Michel, additional, Ducroix, Jean-Pierre, additional, Ménard, Jean-François, additional, Tron, François, additional, and Gilbert, Danièle, additional

Published
2002
Full Text
View/download PDF

250. Bone, cognitive, and anthropometric profiles and their relation to fracture sites in fallers: a cross-sectional study.

Author

Baillet, Maëlle, Morello, Rémy, Vittecoq, Olivier, Chavoix, Chantal, and Marcelli, Christian

Subjects
*EXECUTIVE function, *BONES, *ANTHROPOMETRY, *CROSS-sectional method, *HUMERAL fractures, *ANKLE fractures, *COGNITION, *HIP fractures, *FEAR, *OSTEOPOROSIS, *RISK assessment, *WRIST fractures, *ACCIDENTAL falls, *RESEARCH funding, *FACTOR analysis, *DESCRIPTIVE statistics, *BONE density, *BODY mass index, *BONE fractures, *EDUCATIONAL attainment, *DISEASE risk factors
Abstract

Summary: Risk factors involved in the different osteoporotic fracture locations are not well-known. The results of this study suggest that there is not one typical profile characterising a particular fracture site but that the occurrence of a fracture may result from the combination of different bone, cognitive, and anthropometrics characteristics. Purpose: Risk factors involved in the different osteoporotic fracture locations are not well-known. The aim of this study was to identify the differences in bone, cognitive, and anthropometric characteristics between different fracture sites, and to determine whether the site of a fall-related fracture is related to a specific profile. Methods: One hundred six women aged 55 years and older with a recent fall-related fracture of the hip (n = 30), humerus (n = 28), wrist (n = 32), or ankle (n = 16) were included. Bone, cognitive, and anthropometric characteristics were first compared among the four fracture site groups. Then, a principal component analysis (PCA) was performed and a comparison was made between the four profiles identified by the first two PCA components. Results: The four fracture site groups differed significantly in their education level, bone mineral density (BMD), body mass index (BMI), fear of falling, and number of errors in the Trail Making Test B, an executive function test. Each of the four fracture sites was found in each four PCA profiles, albeit with a different distribution. The profiles differed mainly by bone, cognitive, and anthropometric characteristics, but also by fear of falling. Conclusions: The fall-related fracture sites differ significantly in anthropometric and bone parameters, in fear of falling and in cognitive abilities. There is not one typical bone, cognitive, and anthropometric profile characterising a particular fall-related site, but rather several possible profiles for a given site. This suggests that the fracture site depends on a combination of several characteristics of the patient. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results